Abivax SA (ABVX) Stock Analysis
Healthcare · Biotechnology
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod... Read more
TrendMatrix rates Abivax SA (ABVX) as Sell with moderate confidence. The stock trades at $110.51 with +18.7% upside to the $131.92 price target. Overall score: 5.0/10 across 10 analysis dimensions. Reward/risk ratio: 2.4:1.
Passes 3/4 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags). Fails on weak momentum. Suitability: moderate.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Abivax SA (ABVX) as Sell with moderate confidence. Score 5.0/10.
Take-profit target: $131.92 (+18.7% upside). Reward/risk ratio: 2.4:1. Stop-loss: $102.61.
Consecutive earnings misses (3); Negative momentum.
Abivax SA trades at a P/E of N/A (forward -35.8). TrendMatrix value score: 7.5/10. Verdict: Sell.
14 analysts cover ABVX with a consensus score of 4.3/5. Average price target: $155.
What does Abivax SA do?ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the...
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.